Advances Of LCZ696 In Cardiovascurlar Disease

The over activation of neuroendocrine-cytokines system was deemed to one of the pathology and physiology of heart failure. Inhibition of RAAS is a main emphasis of the therapy to heart failure,Asalso,to increase the level of natriuretic peptides is a way of treat heart failure. LCZ696 which is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) was consist of two perssad Angiotensin II valsartan and neprilysin inhibitor AHU377.It can suppress the RAAS and increase the level of natriuretic peptides to slow down disease progression of heart failure. PARADIGM-HF has shown superiority of LCZ696 compared to ACE inhibitors in stable outpatients with chronic systolic heart failure NYHA stages II and III,and it made LCZ696 became the first medicine that FDA accelerate the approval.Inaddition,some trials expressed that compared with valsartan, LCZ696 has more profits to HF patients than valsatan and associated with preservation of eGFR. It also has the potential to inhibit ventricular remodeling and fibrosis after myocardial infarction in rats.Based on these datas, LCZ696 was safety and is expected to be a way to therapy of heart failure.